Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model

Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model

Approximately 80% of breast cancer (BC) cases are estrogen receptor positive (ER+) and sensitive to hormone treatment; Tamoxifen is a prodrug, and its main plasmatic active metabolites are 4-hydroxytamoxifen (4-OH Tam) and endoxifen. Despite the effectiveness of tamoxifen therapy, resistance can be...

Full description

Bibliographic Details
Main Authors: Angel Pulido-Capiz, Brenda Chimal-Vega, Luis Pablo Avila-Barrientos, Alondra Campos-Valenzuela, Raúl Díaz-Molina, Raquel Muñiz-Salazar, Octavio Galindo-Hernández, Victor García-González
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Pharmaceutics
Subjects:
auraptene
breast cancer
estrogen receptor
resistance
eukaryotic initiation factor-4A complex
Online Access:https://www.mdpi.com/1999-4923/16/9/1179

Internet

https://www.mdpi.com/1999-4923/16/9/1179

Similar Items